NovaBridge Biosciences (NBP) Form 6-K — Oct 26, 2026
NovaBridge Biosciences presented updated Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response rate, 97% disease control rate, and 16.9-month median progression-free survival at the selected 8 mg/kg dose in first-line metastatic gastroesophageal adenocarcinoma, with nearly 18 months of median follow-up. Efficacy was observed across CLDN18.2 expression levels, including 75% ORR in patients with 1-74% expression who are not eligible for currently approved CLDN18.2-targeted therapies. Safety remained manageable, with no Grade 4 or 5 treatment-related adverse events attributed to givastomig.
Key figures
- Dcr 8mg
- 97% (28/29)
- Orr 8mg
- 79% (23/29)
- Median dor
- 15.2 months
- Median pfs
- 16.9 months
- Selected dose
- 8 mg/kg
- Median followup
- 17.8 months
- Orr cldn18 2 1 74
- 75%
- Orr cldn18 2 ge75
- 82%
- Patients in dataset
- 71
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.